JZJawad Ahmad Zahid

Jawad Ahmad Zahid

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jawad Ahmad Zahid has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Surgical outcomes in pelvic reconstruction using robot-assisted rectus abdominis muscle flaps: a systematic review

    by Christina Alexandersen, Angelina Astrid Righult, Jawad Ahmad Zahid, Adile Orhan, Nicco Krezdorn, Ismail Gögenur

    Purpose Pelvic cancer resections increase the risk of pelvic dead space, which increases the risk of postoperative complications. Robot-assisted pelvic reconstruction surgeries are a novel approach that may be beneficial, but it is unclear what impact it has on surgical outcomes in pelvic reconstruction with rectus abdominis muscle flaps. The aim of the study was to systematically review the surgical outcomes of robot-assisted pelvic reconstruction using rectus abdominis muscle flaps in patients with any pelvic cancers. Method A systematic search of the literature was conducted in PubMed, Web of Science, Cochrane Library, and Embase following the PRISMA guidelines, and the final search on all databases was performed on the 13th of May 2024. Studies reporting surgical outcomes of robot-assisted pelvic reconstruction with rectus abdominis muscle flaps were eligible based on predefined criteria. Two reviewers independently screened the literature, extracted data, and assessed risk of bias of included studies. Results Five studies, including 143 patients in total, met the inclusion criteria, comprising two retrospective cohort studies and three case series. Of these, 36 patients underwent robot-assisted pelvic reconstruction using rectus abdominis flaps. All studies reported wound complications, which were lower in the robot-assisted groups compared to open surgery groups. One study reported shorter length of stay. Two studies reported better visualization and avoidance of excessive blood loss when performing robot-assisted surgery. Conclusions Early reports indicate that robot-assisted surgery with flaps in pelvic reconstruction could improve postoperative outcomes. Further research should investigate the potential benefits through larger and controlled patient groups.

  • Open Access

    Questionnaire-Based Global Prevalence of Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis

    by Jawad Ahmad Zahid, Mattias A.S. Henning, Dorra Bouazzi, Gregor B.E. Jemec

    Background: Hidradenitis suppurativa (HS), a chronic inflammatory skin disease affecting intertriginous areas, presents a recurring and debilitating challenge. Even though recent efforts have been made to estimate the overall HS prevalence, variations in screening modalities and missing data from the Global South warrant further investigation. Understanding the HS prevalence is crucial for treatment approaches and pathogenesis. Thus, we aimed to estimate a global HS prevalence based on studies using homogeneous validated questions. Methods: This systematic review was prospectively registered on PROSPERO and adhered to Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Searches in PubMed, Embase, and CINAHL were performed on August 9, 2023. Original reports assessing the HS prevalence in adults using the following two questions were included: “Do you have recurrent boils of the skin?” and “Have you for the past 6 months had 2 or more boils/abscesses in any of the below locations: in the axilla, in the groin, around your genitals, on the buttocks, several locations i.e., first the buttocks then the axilla, etc.?” A pooled prevalence with 95% confidence interval (CI) was calculated with a random-effects model. Results: Eight studies qualified for inclusion, of which the prevalence estimate ranged from 0.7% to 6.4%. The meta-analysis encompassing 49,971 participants revealed a global HS prevalence of 2.5% (95% CI, 1.8–3.5%). Conclusion: This meta-analysis suggests a global HS prevalence of 2.5% using a validated questionnaire. Due to heterogeneity and sparse data from the Global South, this estimate should be interpreted with caution.


  • Open Access

    Major Adverse Cardiovascular Events After Colorectal Cancer Surgery, Oncological Outcomes, and Long-term Mortality: A Nationwide Retrospective Propensity Score-Matched Cohort Study

    by Jawad Ahmad Zahid, Mikail Gögenur, Sarah MD Ekeloef, Ismail Md Gögenur

    Objective: To investigate the occurrence of major adverse cardiovascular events (MACE) following colorectal cancer (CRC) surgery and its association with long-term mortality and oncological outcomes. Background: Cardiovascular complications after noncardiac surgery are a leading cause of perioperative mortality. However, limited knowledge exists on how these complications impact on long-term mortality. Methods: This retrospective cohort study used data from 4 nationwide Danish health registries and included all patients undergoing elective surgery with curative intent for CRC between 2001 and 2019. Patients experiencing MACE, defined as acute myocardial infarction, stroke, new-onset heart failure, or nonfatal cardiac arrest, within 30 days of surgery were matched with those who did not using 1:1 propensity score matching (PSM). The outcomes were all-cause mortality within 1, 3, or 5 years of surgery, as well as 5-year cancer recurrence and disease-free survival. Results: Out of 39,747 patients, 900 (2.3%) had MACE. PSM resulted in 809 pairs of matched patients. Within 1 year of surgery, 110 (13.6%) patients with MACE and 2063 (5.4%) without MACE died (PSM-adjusted hazard ratio [HR] = 1.36; 95% confidence interval [CI] = 1.02–1.83). Within 3 years, 248 (30.6%) patients with MACE and 6268 (16.5%) without MACE died (PSM-adjusted HR = 1.32; 95% CI = 1.07–1.62). Within 5 years, 333 (41.1%) patients with MACE and 9232 (24.3%) without MACE died (PSM-adjusted HR = 1.25; 95% CI = 1.04–1.50). For recurrence and disease-free survival, no statistically significant differences were observed. Conclusions: MACE within 30 days of CRC surgery is associated with higher overall long-term mortality. Investigating causality and preventive measures is urgent in this group.


  • Open Access

    Myocardial injury and long-term oncological outcomes in patients undergoing surgery for colorectal cancer

    by Jawad Ahmad Zahid, Adile Orhan, Noor Al-Huda Hadi, Sarah Ekeloef, Ismail Gögenur

    Purpose Myocardial injury after noncardiac surgery (MINS) is associated with increased mortality and postoperative complications. In patients with colorectal cancer (CRC), postoperative complications are a risk factor for cancer recurrence and disease-free survival. This study investigates the association between MINS and long-term oncological outcomes in patients with CRC in an ERAS setting. Methods This retrospective cohort study was conducted at Zealand University Hospital, Denmark, between June 2015 and July 2017. Patients undergoing CRC surgery were included if troponin was measured twice after surgery. Outcomes were all-cause mortality, recurrence, and disease-free survival within five years of surgery. Results Among 586 patients, 42 suffered MINS. After five years, 36% of patients with MINS and 26% without MINS had died, p = 0.15. When adjusted for sex, age and UICC, the hazard ratio (aHR) for 1-year all-cause mortality, recurrence, and disease-free survival were 2.40 [0.93–6.22], 1.47 [0.19–11.29], and 2.25 [0.95–5.32] for patients with MINS compared with those without, respectively. Further adjusting for ASA status, performance status, smoking, and laparotomies, the aHR for 3- and 5-year all-cause mortality were 1.05 [0.51–2.15] and 1.11 [0.62–1.99], respectively. Similarly, the aHR for 3- and 5-year recurrence were 1.38 [0.46–4.51], and 1.49 [0.56–3.98] and for 3- and 5-year disease-free survival the aHR were 1.19 [0.63–2.23], and 1.19 [0.70–2.03]. Conclusion In absolute numbers, we found no difference in all-cause mortality and recurrence in patients with and without MINS. In adjusted Cox regression analyses, the hazard was increased for all-cause mortality, recurrence, and disease-free survival in patients with MINS without reaching statistical significance.


  • Open Access

    Effect of melatonin in patients with low anterior resection syndrome (MELLARS): a study protocol for a randomised, placebo-controlled, crossover trial

    by Jawad Ahmad Zahid, Michael Tvilling Madsen, Orhan Bulut, Peter Christensen, Ismail Gögenur

    Introduction After rectal cancer surgery, a majority of patients suffer from sequelae known as low anterior resection syndrome (LARS). It is a collection of symptoms consisting of flatus and/or stool incontinence, evacuation frequency, re-evacuation and urgency. The circadian hormone, melatonin, has shown to possess anti-inflammatory properties, and in high doses, it reduces bowel movements. The aim of the study is to investigate if locally administered melatonin has an alleviating effect on LARS. Secondarily, the effect of melatonin on bowel movements, other patient-reported symptoms, quality of life, depression, anxiety, sleep disturbances, motilin levels and rectal mucosa histology will be examined. Methods and analysis This is a randomised, placebo-controlled, double-blinded, two-period crossover trial. The participants are randomised to 28 days of 25 mg melatonin administered rectally via an enema daily (or placebo) followed by a 28-day washout and then 28 days of placebo (or melatonin). Three participants will be included in an internal feasibility test. They will receive 25 mg of melatonin daily for 28 days. Data from these participants will be used to assess the feasibility of the rectally administered melatonin and to analyse the course of recruitment and outcome measurements. Afterwards, 18 participants will be included in the crossover trial. The severity of the LARS symptoms will be evaluated using the LARS Score on the first and last day of each treatment period. Ethics and dissemination The Regional Ethics Committee, the Danish Medicines Agency and the Data and Development Support in Region Zealand approved this study. The study will be performed according to the Helsinki II declaration. Written informed consent will be obtained from all participants. The results of the study will be submitted to peer-reviewed journals for publication and presented at congresses. Trial registration numbers EudraCT Registry (2020-004442-11) and ClinicalTrial.gov Registry (NCT05042700).


  • Risk of Atopic Disorders in Patients with Chronic Urticaria: A Systematic Review and Meta-Analysis

    by Ditte Georgina Zhang, Jawad Ahmad Zahid, Zarqa Ali, Simon Francis Thomsen

    Background: Chronic urticaria (CU) has been associated with several systemic and autoimmune disorders. The association with atopic disorders is however controversial. The objective of this study was to perform a systematic review and meta-analysis to assess the association between CU and the atopic disorders: atopic dermatitis (AD), asthma, and allergic rhinoconjunctivitis (ARC). Methods: Search hits from PubMed, Embase, Cochrane Library, and Web of Science were systematically reviewed. English papers from 2000 to present, containing original data of the association (prevalence, incidence, or risk) between CU and any atopic disorder(s), were included. Pooled point prevalence and OR with 95% confidence intervals were calculated with a random effects model. Results: A total of 8,108 search hits were screened and reviewed. Thirty-eight studies met all inclusion criteria. The estimated pooled point prevalence of AD, asthma, and ARC in CU was 7% (5–11%, I2 = 99%), 12% (9–15%, I2 = 100%), and 22% (16–29%, I2 = 100%), respectively. Pooled ORs were estimated to 2.75 (2.05–3.68, I2 = 94%) for AD, 1.87 (1.01–3.45, I2 = 100%) for asthma, and 2.94 (1.84–4.68, I2 = 100%) for ARC. Conclusion: Pooled point prevalences of atopic disorders in CU were comparable to the general population. However, studies that compared prevalences with controls from the same population all found a significantly increased risk of atopic disorders in CU. Results should however be interpreted with caution as high heterogeneity was found in all analyses.


  • Myocardial Injury After Colorectal Cancer Surgery and Postoperative 90-Day Mortality and Morbidity: A Retrospective Cohort Study

    by Jawad A. B.M.Sc. Zahid, Adile Orhan, Sarah Ph.D. Ekeloef, Ismail D.M.Sc. Gögenur

    BACKGROUND: Myocardial injury after noncardiac surgery is a strong predictor of 30-day mortality and morbidity. OBJECTIVE: The purpose of this study was to examine the incidence of myocardial injury in patients undergoing colorectal cancer surgery in an enhanced recovery after surgery protocol and its association with 90-day mortality and morbidity. DESIGN: This is a retrospective cohort study. SETTING: This study was conducted at Zealand University Hospital, Denmark, between June 2015 and July 2017. PATIENTS: Adult patients undergoing colorectal cancer surgery were included if troponin was measured at least twice during the first 7 days after surgery. The patients were followed for 90 days. MAIN OUTCOME MEASURES: Myocardial injury was defined as an elevated troponin I measurement (>45 ng/L) without evidence of a nonischemic origin causing the elevation. Ninety-day mortality and complications were assessed. RESULTS: A total of 586 patients were included of which 42 were diagnosed with myocardial injury. Thirteen patients (2%) died within 90 days of surgery. There was no significant difference in 90-day mortality between patients with and without myocardial injury (5% (2/42) versus 2% (11/544); p = 0.24). We found a higher incidence of postoperative complications within 90 days of surgery in the myocardial injury group than in the nonmyocardial injury group (43% (18/42) versus 20% (107/544); p < 0.01). We found a significant difference between the myocardial injury group and nonmyocardial injury group in terms of medical complications (33% (14/42) versus 9% (50/544); p < 0.01) but not surgical complications (19% (8/42) versus 16% (85/544); p = 0.56). Myocardial injury was an independent predictor of postoperative complications within 90 days of surgery (adjusted OR, 2.69; 95% CI, 1.31–5.55). LIMITATIONS: This study was limited by its retrospective design. CONCLUSION: Myocardial injury occurs frequently in patients undergoing colorectal cancer surgery in an enhanced recovery after surgery protocol. Patients with myocardial injury did not have a significantly higher 90-day mortality but had higher risk of 90-day postoperative complications than patients without myocardial injury. Future research should examine the prevention and treatment of myocardial injury. See Video Abstract at http://links.lww.com/DCR/B692. LESIÓN MIOCÁRDICA DESPUÉS DE LA CIRUGÍA DE CÁNCER COLORRECTAL Y MORTALIDAD Y MORBILIDAD POSOPERATORIAS A LOS 90 DÍAS: UN ESTUDIO DE COHORTE RETROSPECTIVE: ANTECEDENTES: La lesión del miocardio después de una cirugía no cardíaca es un fuerte predictor de mortalidad y morbilidad a los 30 días. OBJETIVO: El propósito fue examinar la incidencia de lesión miocárdica en pacientes sometidos a cirugía de cáncer colorrectal en un protocolo de recuperación mejorada después de la cirugía y su asociación con la mortalidad y morbilidad a los 90 días. DISEÑO: Estudio de cohorte retrospectivo. AJUSTE: Realizado en el Hospital Universitario de Zelanda, Dinamarca, entre junio de 2015 y julio de 2017. PACIENTES: Se incluyeron pacientes adultos sometidos a cirugía de cáncer colorrectal, si la troponina se midió al menos dos veces durante los primeros siete días después de la cirugía. Los pacientes fueron seguidos durante 90 días. PRINCIPALES MEDIDAS DE RESULTADO: La lesión miocárdica se definió como una medición de troponina I elevada (> 45 ng / l) sin evidencia de una etiología no isquémica que causara la elevación. Se evaluaron la mortalidad y las complicaciones a los noventa días. RESULTADOS: Se incluyeron un total de 586 pacientes, de los cuales 42 fueron diagnosticados de lesión miocárdica. Trece pacientes (2%) murieron dentro de los 90 días posteriores a la cirugía. No hubo diferencias significativas en la mortalidad a 90 días entre los pacientes con y sin lesión del miocardio, 5% [2/42] versus 2% [11/544], p = 0,24. Encontramos una mayor incidencia de complicaciones posoperatorias dentro de los 90 días de la cirugía en el grupo de lesión miocárdica en comparación con el grupo de lesión no miocárdica, 43% [18/42] versus 20% [107/544], p p p = 0,56). La lesión miocárdica fue un predictor independiente de complicaciones posoperatorias dentro de los 90 días posteriores a la cirugía (razón de probabilidades ajustada: 2,69; intervalo de confianza del 95%: 1,31 - 5,55). LIMITACIONES: Limitado por su diseño retrospectivo. CONCLUSIÓN: La lesión del miocardio ocurre con frecuencia en pacientes sometidos a cirugía de cáncer colorrectal en un protocolo de recuperación mejorada después de la cirugía. Los pacientes con lesión miocárdica no tuvieron una mortalidad significativamente mayor a los 90 días, pero tuvieron un mayor riesgo de complicaciones posoperatorias a los 90 días en comparación con los pacientes sin lesión miocárdica. Las investigaciones futuras deben examinar la prevención y el tratamiento de la lesión miocárdica. Consulte Video Resumen en http://links.lww.com/DCR/B692.


  • The effect of melatonin on depressive symptoms and anxiety in patients after acute coronary syndrome: The MEDACIS randomized clinical trial

    by Michael Tvilling Madsen, Jawad Ahmad Zahid, Christine Hangaard Hansen, Ole Grummedal, Jessica Roberts Hansen, Anders Isbrand, Ulla Overgaard Andersen, Lars Juel Andersen, Mustafa Taskiran, Erik Simonsen, et al.


  • The effect of melatonin on endothelial dysfunction in patients after acute coronary syndrome: The MEFACS randomized clinical trial

    by Jawad Ahmad Zahid, Anders Isbrand, Jakob Kleif, Anne‐Marie Voigt Schou‐Pedersen, Jens Lykkesfeldt, Michael Tvilling Madsen, Ismail Gögenur

    Endothelial dysfunction (ED) precedes acute coronary syndrome. Oxidative stress results in ED but is reversible. Melatonin is aside from being a circadian hormone, also an antioxidant. The aim of this study was to investigate whether 25 mg melatonin administered for twelve weeks following acute coronary syndrome (ACS) could improve ED. In this placebo‐controlled randomized trial, ED was measured as reactive hyperemia index (RHI) at baseline, day 14, and day 84. The effect was assessed using a generalized estimating equation adjusted for the baseline RHI. As secondary outcome, the concentrations of three biomarkers were measured: l‐arginine, asymmetric dimethylarginine, and uric acid. Thirty‐one patients were included in the study. The intention‐to‐treat analysis of the primary outcome had 26 patients due to missing data. The estimated marginal mean difference in RHI at day 14 and day 84 between the groups was 0.15 (95% CI: 0.29‐0.01, P = .039) in favor of the placebo group. No significant differences in the biomarker concentrations were found. Melatonin treatment after ACS did not improve but may have aggravated ED. The significant difference between groups was in favor of placebo, but this might be due to the effect of missing data or uneven distribution of comorbidities.